Boston Partners’s Qiagen QGEN Stock Holding History

Boston Partners’s Portfolio QGEN Stock Details QGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Sell	28,267 -3,597,424	-99%	-$134M	﹤0.01%	667
2026 Q1	$145M	Sell	3,625,691 -354,325	-9%	-$16.8M	0.15%	182
2025 Q4	$179M	Sell	3,980,016 -35,632	-0.9%	-$1.65M	0.19%	173
2025 Q3	$179M	Buy	+4,015,648	New	+$192M	0.18%	171

Other funds holding QGEN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners's QGEN Position: Q2 2026 in Review

Boston Partners reduced its Qiagen (QGEN) stake by 99% in Q2 2026, selling an estimated $134M and leaving 28,267 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #667.

Boston Partners first reported a position in QGEN in Q3 2025 and has held it in 4 quarters since. The position peaked at $179M in Q3 2025. 336 funds tracked by Wall St. Rank hold QGEN as of Q2 2026.

Boston Partners held 28,267 shares of Qiagen worth $1.11M as of Q2 2026.
Boston Partners sold 3,597,424 Qiagen shares in Q2 2026, an estimated $134M.
Qiagen made up ﹤0.01% of Boston Partners's portfolio in Q2 2026, its #667 holding.
Boston Partners first reported a position in Qiagen in Q3 2025 and has held it in 4 quarters since.
Boston Partners's Qiagen position peaked at $179M in Q3 2025.
336 funds tracked by Wall St. Rank held Qiagen as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.